After a surprise rejection at the beginning of 2026, the FDA has agreed to reconsider a T-cell therapy based on the same ...
From 100 to 600 patients: to support patients suffering from acne, Avène, Pierre Fabre Laboratories' leading brand, is strengthening the robustness of its clinical studies via data augmentation ...
Atara Biotherapeutics said the FDA outlined a potential pathway for resubmitting the tabelecleucel application after a recent ...
Auctim, one of Europe’s leading online auction houses, announces an exceptional international auction featuring two rare sculptural works by Belgian artist Jan Fabre, including a landmark edition of ...
PFL-721 and PFL-241 are mutant-specific EGFR inhibitors with best-in-class potential, being developed as treatment options for emergent and unmet medical needs in non-small cell lung cancer ("NSCLC") ...
First allogeneic T-Cell therapy BLA offers hope to EBV+ PTLD patients who have limited treatment options and lifespan measured in only a few weeks to months following failure of initial treatment EBV+ ...
Pierre Fabre Pharmaceuticals, Inc. (PFP), announces it has aligned with FDA on a potential path forward for resubmission of the BLA for tabelecleucel, an allogeneic T-cell therapy with a proposed ...
Archbishop Shelton J. Fabre meets the staff of the Office of Catholic Schools of the Archdiocese of Louisville, Ky., after celebrating Mass at Holy Family Church in Louisville Feb. 8, 2022. Pope ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results